Vyriad: Funding, Investors & Team (Sep 2026)
Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.
Vyriad has raised $54.5M across 2 funding rounds on record, the most recent a Series B of $25.0M announced in Dec 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vyriad Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Vyriad Funding Rounds
Vyriad raised $29.5M in a Series B announced in May 2022.
3.6 years later, a Series B of $25.0M was announced in Dec 2025.
Vyriad Founders and Leadership Team
Contact details for the Vyriad team: 1 of 2 have an email address on file.
Start 14-day free trial →Vyriad Funding Compared to Other Biotechnology Startups
Vyriad's latest round of $25.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vyriad in Biotechnology and Rochester
Companies Similar to Vyriad
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Vyriad Funding FAQs
What does Vyriad do?
Vyriad is a clinical-stage company developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs. The potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.
How much funding has Vyriad raised?
Vyriad has raised $54.5M across 2 rounds on record. The most recent is a Series B of $25.0M announced in Dec 2025.
When did Vyriad last raise funding?
Vyriad's most recent funding round on record is a Series B of $25.0M, announced in Dec 2025.
Who founded Vyriad?
FundedIQ lists Kah Whye Peng (Founder), Kah-Whye Peng (Founder) at Vyriad.
Where is Vyriad headquartered?
Vyriad is based in Rochester, Minnesota, United States.
How many employees does Vyriad have?
Vyriad is in the 11-50 employee band.
How does Vyriad's funding compare to other Biotechnology startups?
Vyriad's latest round of $25.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Vyriad Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vyriad is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.